Can a pill and injection combo beat AML without harsh chemo?
NCT ID NCT07748455
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This trial tests a combination of two drugs, azacitidine and venetoclax, as the first treatment for young, fit adults (ages 18-50) with newly diagnosed acute myeloid leukemia (AML). The goal is to see how many patients achieve complete remission after one or two cycles of this therapy. If successful, this approach could offer a less intensive alternative to standard chemotherapy, potentially leading to a cure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A combination of two drugs: azacitidine (given by injection or IV) and venetoclax (taken as a pill by mouth).
- What this could lead to
- If this works, it could offer a new, less intense first treatment for young adults with AML, potentially leading to remission and a path to cure without needing standard chemotherapy.
- What could go wrong
- This is a phase II trial with only 60 patients, so results may not be definitive. The drugs can cause side effects like low blood counts and infections, and not all patients may respond.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National University of Medical Sciences, Clinical Trial Unit
Rawalpindi, 46000, Pakistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tailored chemo cocktail outsmart a common leukemia?
- Can new drug cocktails beat back Hard-to-Treat leukemia?
- Can a pill tackle Tough-to-Treat leukemia?
- Can a triple-drug combination tame AML without intensive chemo?
- Personalized dosing may improve stem cell transplant survival in blood cancer patients
- Can pressurized oxygen boost cord blood transplants?